Blue Danube Systems Introduces BeamPlanner™ Optimization Software and Expands Leadership in FDD Massive MIMO Commercial Engagements
Blue Danube Systems, a provider of mobile wireless access solutions that significantly and cost-effectively increase network capacity and enhance quality of service, today announced the release of BeamPlanner™, a software platform used in conjunction with the company’s BeamCraft™ active antenna systems that enables wireless carriers to optimize RF patterns to improve cell capacity and coverage based on siting conditions and dynamic user distributions.
BeamPlanner maximizes the effectiveness of multi-site active antenna deployment with sophisticated network optimization intelligence by directing RF energy to where the traffic is while steering clear of interference from neighboring sites. In addition, BeamPlanner automates network-wide configuration, scheduling, and management of BeamCraft systems and integrates seamlessly with existing wireless carrier’s RF planning workflows to simplify design in today’s dynamic mobile world.
Blue Danube recently completed its third commercial trial and first outside North America with Telstra in Australia where BeamPlanner was first used at a customer site. The Telstra trials, conducted in the 1800 MHz FDD spectrum, further demonstrated BeamCraft’s capability to form and switch beams with high fidelity to enhance network performance through a combination of improved coverage, capacity and interference reduction. The company’s earlier trials in the PCS and AWS spectrum, which started a year ago, established the industry’s first Massive MIMO systems in FDD networks. With the latest demonstrations, BeamCraft is also the first Massive MIMO system to be implemented in three different FDD bands with multiple operators.
In addition to the new trial, the company also received its first revenue order from a North American customer for a multi-site BeamCraft FDD deployment where BeamPlanner will be instrumental as part of the planning process to deliver an optimized site solution. More trials are planned for Europe, Asia and Latin America later this year, and the company will be opening an office in Europe in October to support the growing number of customers and partners.
Blue Danube also announced today that John Shelnutt is joining as Vice President of Sales as the company expands its executive team after raising its first Series-C funding recently in a round led by Silver Lake Kraftwerk. John has a broad background in the telecommunications industry, most recently at Cisco as Vice President/GM of Cisco’s Mobility Domain global business and before that as Cisco’s senior executive leader for AT&T. Prior to Cisco, John was the Executive Vice President of Goodman Networks, a wireless network deployment and services company. After beginning his career at Nortel, he spent 12 years at Alcatel and then Alcatel-Lucent where he held leadership positions in the DSL and Mobility businesses.
“We continue to make strong progress with additional commercial trials and are very excited to have John Shelnutt join our team to drive our sales growth and expansion,” said Dr. Mark Pinto, CEO of Blue Danube. “We also welcome Adam Grosser from Silver Lake to Blue Danube’s Board of Directors. Together with our strong investors and partners, we are confident that we will accelerate volume deployments and expand our product development to build a comprehensive 5G portfolio to address multiple markets.”
For more information, please visit www.bluedanube.com.
About Blue Danube System
Blue Danube Systems provides mobile wireless communications solutions that significantly and cost-effectively expand network capacity to enhance quality of service. The company’s proprietary approach combines reliable hardware and intelligent software to enable a significant increase in capacity, utilizing existing infrastructure and today’s mobile devices. Blue Danube Systems is backed by investors including Sequoia Capital, Northgate and AT&T and has locations in Warren, NJ and Santa Clara, CA. Blue Danube Systems is listed among EE Times Silicon 60 and is a winner of FierceWireless Fierce 15 for 2016. For more information, please visit www.bluedanube.com.
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life19.11.2017 16:31 | Pressemelding
Sharjah, the third largest of the United Arab Emirate’s seven emirates, was the host for the MENA region’s first ever ‘Global Relay for Life,’ (RFL) a 24-hour walkathon that is the biggest fundraising event for cancer in the world. Conducted in conjunction with the American Cancer Society, the event was organised by Friends of Cancer Patients (FoCP), a non-profit organisation that supports cancer patients and their families. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005048/en/ During MENA's first Global Relay For Life walkathon - Source: Friends of Cancer Patients Taking place November 17-18 at the American University Sharjah, the inaugural UAE RFL saw more than 2,000 relayers participating in the overnight event, with a large number of individuals and institutions involved including 52 sch
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00 | Pressemelding
AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20 | Pressemelding
AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute
Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11 | Pressemelding
The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other
Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn17.11.2017 16:20 | Pressemelding
Madison Realty Capital (MRC) announced the closing of a $64.0 million construction loan for 200 Kent Avenue, a 117,326 square foot mixed-use development located in Williamsburg, Brooklyn. The retail portion of the property, which will include over 600 feet of frontage, will be anchored by a popular national grocery chain. Overall, the project will offer 50,101 square feet of retail space, 22,055 square feet of office and restaurant space, and 45,170 square feet of parking. “We continue to establish MRC as the one-stop shop for financing transitional real estate, including ground-up development deals like 200 Kent Avenue,” said Josh Zegen, Co-Founder and Managing Principal of MRC. “In this case, we’re working with a repeat MRC borrower who understands our ability to execute efficiently, given our firm’s up-to-the minute knowledge of local market conditions and non-bureaucratic approach to
Ncardia Announces Completion of €10.5M Investment Round17.11.2017 12:31 | Pressemelding
Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural solutions based on its best-in-class human induced pluripotent stem cell (iPSC)-derived technology, today announced the completion of a €10.5 million series B financing round. The round was led by Épimède, a Belgium venture capital firm. Ncardia is a privately-held company with operations in Europe and the US, that produces and commercializes high-quality, fully-functional human iPSC-derived cardiovascular and neuronal cell types. Using its cell products, Ncardia develops and commercializes assay services for drug safety and efficacy testing. Additionally the company has built up a strong portfolio of patents covering the use of stem cell models for these applications. Stefan Braam, CEO of Ncardia, commented: “At Ncardia, important progress h
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom